Critical Contrast: Anteris Technologies Global (NASDAQ:AVR) & LeMaitre Vascular (NASDAQ:LMAT)

Anteris Technologies Global (NASDAQ:AVR) and LeMaitre Vascular (NASDAQ:LMAT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, analyst recommendations, earnings, valuation and risk.

Institutional & Insider Ownership

84.6% of LeMaitre Vascular shares are held by institutional investors. 4.5% of Anteris Technologies Global shares are held by company insiders. Comparatively, 7.4% of LeMaitre Vascular shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Anteris Technologies Global has a beta of 2.02, meaning that its share price is 102% more volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Anteris Technologies Global and LeMaitre Vascular, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anteris Technologies Global	1	1	3	0	2.40
LeMaitre Vascular	0	5	3	0	2.38

Anteris Technologies Global currently has a consensus price target of $14.00, indicating a potential upside of 125.81%. LeMaitre Vascular has a consensus price target of $108.25, indicating a potential upside of 36.52%. Given Anteris Technologies Global’s stronger consensus rating and higher probable upside, research analysts clearly believe Anteris Technologies Global is more favorable than LeMaitre Vascular.

Earnings and Valuation

This table compares Anteris Technologies Global and LeMaitre Vascular”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anteris Technologies Global	$1.91 million	316.46	-$94.14 million	($1.95)	-3.18
LeMaitre Vascular	$249.60 million	7.27	$57.73 million	$2.75	28.83

LeMaitre Vascular has higher revenue and earnings than Anteris Technologies Global. Anteris Technologies Global is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Anteris Technologies Global and LeMaitre Vascular’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Anteris Technologies Global	-4,637.48%	-61.24%	-54.97%
LeMaitre Vascular	23.51%	15.33%	9.97%

Summary

LeMaitre Vascular beats Anteris Technologies Global on 9 of the 13 factors compared between the two stocks.

About Anteris Technologies Global

Anteris Technologies Global is a medical technology company focused on developing treatments for structural heart disease, particularly aortic valve conditions. Its work centers on transcatheter heart valve technology, which is designed to replace a damaged valve through a minimally invasive procedure. The company’s lead product is the DurAVR transcatheter heart valve. It is made using Anteris’ ADAPT tissue technology, which processes bovine pericardial tissue for use in medical devices. The valve is designed to resemble the structure and function of a healthy aortic valve.

About LeMaitre Vascular

LeMaitre Vascular develops, manufactures and markets medical devices used primarily in the treatment of vascular disease. Its products support procedures performed by vascular surgeons and include vascular grafts, embolectomy catheters, carotid shunts, valvulotomes and other instruments used in vascular surgery. Founded in 1983 by vascular surgeon George LeMaitre, the company is headquartered in Burlington, Massachusetts. Its products are sold to hospitals and medical professionals around the world through a combination of direct sales and distributors.